Novo Nordisk is to invest more than $4bn (£3.2bn) in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic.
Denmark’s biggest pharmaceuticals company said it would spend $4.1bn building a second filling and finishing facility in Clayton, North Carolina, one of the biggest manufacturing investments in its history. Its drugs are injected by users once a week, and come in pre-filled pens.
